Shaomeng Wang
Chief Scientific Officer
Drug Design and Discovery
OncoFusion Therapeutics
United States of America
Biography
Dr. Wang is a Co-Founder of OncoFusion and will serve as its Chief Scientific Officer. Dr. Wang is an internationally recognized expert in structure-based drug design and discovery. Dr. Wang is Warner-Lambert/Parke-Davis Professor in Medicine and Professor of Medicinal Chemistry, Medicine and Pharmacology at the University of Michigan. Dr. Wang serves as Director of the Cancer Drug Discovery Program and Co-Director of the Experimental Therapeutics Program at the University of Michigan Comprehensive Cancer Center, as well as Director of Therapeutics Discovery at the Michigan Center for Translational Pathology. Dr. Wang co-founded and has served on the Board of Directors of the cancer therapeutics companies Ascenta (2004-2007) and Ascentage (2009-present). Ascenta raised over $85M in venture funds and has licensed two of its drugs discovered by Dr. Wang’s laboratory to Sanofi and DebioPharm with >$500M milestone payments and additional royalties on sale. Ascentage has raised significant funding from a pharmaceutical company (3SBio) and governments and is progressing multiple drug candidates into clinical development discovered in Dr. Wang’s laboratory.
Research Interest
Drug Design and Discovery
